At Astellas R&D Day, Enzalutamide And In-house Tech In The Spotlight
This article was originally published in PharmAsia News
Executive Summary
Astellas has tried to build oncology knowhow in the past six years, and while licensed compounds approach approval, Phase II in-house compounds may show whether it can be a global leader.